Docetaxel: Chemotherapy drug likely to be less effective in overweight, obese women with breast cancer

Docetaxel: Chemotherapy drug likely to be less effective in overweight, obese women with breast cancer

Treatment with docetaxel, a common chemotherapy drug, might have lesser benefits for breast cancer patients who are overweight or obese, according to new research.

An international team of researchers based this conclusion on a retrospective analysis of data from a large clinical trial. Their study was published in the Journal of Clinical Oncology.

In most European countries, more than 50 per cent of women are overweight or obese (with a body mass index (BMI) above 25 kg/m2, as defined by the WHO). In the United States, this is the case for over 63 per cent of women and this proportion is expected to further increase in the coming years.

It is not widely known, but obese women have a higher risk of getting breast cancer and obese breast cancer patients have a higher risk of relapsing. Moreover, while many cancer patients are overweight or obese, the efficacy of anticancer drugs according to their BMI is generally not known.

For the study, a team led by researchers from KU Leuven and the Institut Jules Bordet (Belgium), the University of Milan, and the National Cancer Institute (Italy) analysed data from a clinical trial with over 2800 breast cancer patients that started around the turn of the millennium.

Patient data were collected over the course of more than ten years. The patients in the trial were treated with a combination of chemotherapy drugs with or without docetaxel, one of the most widely used chemotherapy drugs in the world. The researchers then looked at how many patients relapsed and how many had passed away.

Their statistical analysis of the data shows that overweight and obese patients who received docetaxel as part of their treatment had poorer outcomes than lean patients (BMI between 18.5 and 25 kg/m2). This difference was not observed in patients who received the chemotherapy regimen that did not include docetaxel.

“Docetaxel is a lipophilic drug, suggesting that fat present in the body could absorb part of the drug before it can reach the tumour,” explained Professor Christine Desmedt from the KU Leuven Laboratory for Translational Breast Cancer Research.

The results raise concerns about treating overweight and obese cancer patients with docetaxel.

“If follow-up research confirms that this finding is solely related to the pharmacological characteristics of docetaxel, this might also apply to patients with other cancer types that are treated with docetaxel, such as prostate or lung cancer. These results also make us wonder whether other chemotherapy drugs from the same family, like paclitaxel, will show the same effect,” explained Professor Desmedt.

Professor Desmedt added, “more research is needed before changes in treatment can be implemented. Patients who have concerns about docetaxel can discuss these with their doctor. In general, the public needs to be better informed about the link between BMI and breast cancer.”

“In the medical and research world, we need to pay more attention to how obesity affects the biology, progression, and treatment efficacy of breast cancer. Much work remains to be done in this field,” said Professor Biganzoli of the Unit of Medical Statistics and the Data Science Research Center, the University of Milan and the Italian National Cancer Institute.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)

Follow more stories on Facebook and Twitter

Source: Read Full Article